Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 5Gastrointestinal 3Plasma cell 2Other hematologic neoplasm 2CNS 2Sarcoma 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Multiple Myeloma 2

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × sonidegib × Plasma cell × Clear all
NCT02086552 2021-12-03

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Mayo Clinic

Phase 2 Completed
28 enrolled 9 charts
Plasma cell

Multiple Myeloma

NCT02254551 2017-02-16

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

SCRI Development Innovations, LLC

Phase 2 Terminated
7 enrolled 6 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡